Management of Asthma: The Current US and European Guidelines

  • Ashwini P. Reddy
  • Meera R. GuptaEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 795)


Asthma management guidelines aim to improve the implementation of current knowledge into daily clinical practice by establishing a consensus of scientific practices for the management of asthma. Initial guidelines were based on consensus of expert opinion in order to employ a severity-based classification system as a guide to treatment. However, advances in asthma research led to the development of evidence-based guidelines and a major paradigm shift to control-based asthma management. Control-based management is central to the published guidelines developed by The National Heart, Lung, and Blood Institute (NHLBI), The Global Initiative for Asthma (GINA), and The British Thoracic Society (BTS), each one using the same volume of evidence but emphasizing aspects particular to their specific patient populations and socioeconomic needs. This chapter summarizes the evolution of these guidelines and summarizes the key points and evidence used in the recommendations for the assessment, monitoring, and management of asthma in all ages, with particular emphasis on the NHLBI guidelines.


Asthma Asthma: management NHLBI guidelines Asthma: drug therapy Humans Practice guidelines as topic GINA guidelines BTS guidelines Asthma: pediatric guidelines Asthma: diagnosis Asthma: treatment 


  1. Adams N, Bestall J, Jones PW (2001) Inhaled fluticasone propionate for chronic asthma. Cochrane Database Syst Rev CD003135Google Scholar
  2. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J et al (1998) A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 102:50–56PubMedGoogle Scholar
  3. Anhoj J, Bisgaard AM, Bisgaard H (2002) Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics 109:E40PubMedGoogle Scholar
  4. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al (2004) Asthma severity and medical resource utilisation. Eur Respir J 23:723–729PubMedGoogle Scholar
  5. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA (2004) Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 170:426–432PubMedGoogle Scholar
  6. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K (1999) A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 103:414–421PubMedGoogle Scholar
  7. Bateman ED, Ha B, Bousquet J, Busse WW, Clark TJH, Ra P et al (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170:836–844PubMedGoogle Scholar
  8. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143–178PubMedGoogle Scholar
  9. Bertelsen A, Andersen JB, Busch P, Daugbjerg P, Friis B, Hansen L et al (1986) Nebulised sodium cromoglycate in the treatment of wheezy bronchitis. A multicentre double-blind placebo controlled study. Allergy 41:266–270PubMedGoogle Scholar
  10. Bisgaard H (1999) Future options for aerosol delivery to children. Allergy 54(Suppl 49):97–103PubMedGoogle Scholar
  11. Bisgaard H (2003a) Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 36:391–398PubMedGoogle Scholar
  12. Bisgaard H (2003b) A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167:379–383PubMedGoogle Scholar
  13. Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L et al (2000) Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105:1123–1129PubMedGoogle Scholar
  14. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H (2004) Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125:1378–1386PubMedGoogle Scholar
  15. Bousquet J, Clark TJH, Hurd S, Khaltaev N, Lenfant C, O’byrne P et al (2007) GINA guidelines on asthma and beyond. Allergy 62:102–112PubMedGoogle Scholar
  16. BTS/SIGN (2008a) British guideline on the management of asthma. Thorax 63(Suppl 4):iv1–iv121Google Scholar
  17. BTS/SIGN (2008b) British guideline on the management of asthma. Respir Med 98:832–837Google Scholar
  18. Busse WW (1993) What role for inhaled steroids in chronic asthma? Chest 104:1565–1571PubMedGoogle Scholar
  19. Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S et al (2001) Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 107:461–468PubMedGoogle Scholar
  20. CAMP (2000) Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 343:1054–1063Google Scholar
  21. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD (2000) A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 162:1403–1406PubMedGoogle Scholar
  22. Colice GL, Burgt JV, Song J, Stampone P, Thompson PJ (1999) Categorizing asthma severity. Am J Respir Crit Care Med 160:1962–1967PubMedGoogle Scholar
  23. Crompton GK, Ayres JG, Basran G, Schiraldi G, Brusasco V, Eivindson A et al (1999) Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med 159:824–828PubMedGoogle Scholar
  24. Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P et al (1993) A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 104:1352–1358PubMedGoogle Scholar
  25. Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M et al (1998) Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187–1194PubMedGoogle Scholar
  26. Diette GB, Krishnan JA, Wolfenden LL, Skinner EA, Steinwachs DM, Wu AW (2004) Relationship of physician estimate of underlying asthma severity to asthma outcomes. Ann Allergy Asthma Immunol 93:546–552PubMedGoogle Scholar
  27. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR et al (1992) Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669–674PubMedGoogle Scholar
  28. Dodge R, Martinez FD, Cline MG, Lebowitz MD, Burrows B (1996) Early childhood respiratory symptoms and the subsequent diagnosis of asthma. J Allergy Clin Immunol 98:48–54PubMedGoogle Scholar
  29. DuBuske LM, Grossman J, Dube LM, Swanson LJ, Lancaster JF (1997) Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am J Manag Care 3:633–640PubMedGoogle Scholar
  30. Ducharme FM (2003) Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 326:621PubMedGoogle Scholar
  31. Duddridge M, Ward C, Hendrick DJ, Walters EH (1993) Changes in bronchoalveolar lavage inflammatory cells in asthmatic patients treated with high dose inhaled beclomethasone dipropionate. Eur Respir J 6:489–497PubMedGoogle Scholar
  32. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337:1412–1418PubMedGoogle Scholar
  33. Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW et al (2001) FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 107:61–67PubMedGoogle Scholar
  34. Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, Lozano P, Janson SL et al (2002) The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 166:1044–1049PubMedGoogle Scholar
  35. Fuhlbrigge AL, Guilbert T, Spahn J, Peden D, Davis K (2006) The influence of variation in type and pattern of symptoms on assessment in pediatric asthma. Pediatrics 118:619–625PubMedGoogle Scholar
  36. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P (2005) Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 116:360–369PubMedGoogle Scholar
  37. Geller-Bernstein C, Sneh N (1980) The management of bronchial asthma in children under the age of 3 1/2 years using Intal (sodium cromoglycate) administered by Spinhaler. Clin Allergy 10(Suppl):503–508PubMedGoogle Scholar
  38. GINA (2011) Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MDGoogle Scholar
  39. Glass J, Archer LN, Adams W, Simpson H (1981) Nebulised cromoglycate, theophylline, and placebo in preschool asthmatic children. Arch Dis Child 56:648–651PubMedGoogle Scholar
  40. Graham LM (2006) Classifying asthma. Chest 130:13S–20SPubMedGoogle Scholar
  41. Greening AP, Ind PW, Northfield M, Shaw G (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344:219–224PubMedGoogle Scholar
  42. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X et al (2005) Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev CD005533Google Scholar
  43. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ et al (2006) Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354:1985–1997PubMedGoogle Scholar
  44. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K et al (1991) Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 325:388–392PubMedGoogle Scholar
  45. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC (2003) Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 326:1115PubMedGoogle Scholar
  46. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309–316PubMedGoogle Scholar
  47. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH (2003) Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97:555–562PubMedGoogle Scholar
  48. Israel E, Cohn J, Dube L, Drazen JM (1996) Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275:931–936PubMedGoogle Scholar
  49. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA (1992) Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 145:890–899PubMedGoogle Scholar
  50. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR (1999) Development and validation of a questionnaire to measure asthma control. Eur Respir J 14:902–907PubMedGoogle Scholar
  51. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM et al (1996) Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med 153:1739–1748PubMedGoogle Scholar
  52. Katz PP, Yelin EH, Eisner MD, Blanc PD (2002) Perceived control of asthma and quality of life among adults with asthma. Ann Allergy Asthma Immunol 89:251–258PubMedGoogle Scholar
  53. Kelly A, Tang R, Becker S, Stanley CA (2008) Poor specificity of low growth hormone and cortisol levels during fasting hypoglycemia for the diagnoses of growth hormone deficiency and adrenal insufficiency. Pediatrics 122:e522–e528PubMedGoogle Scholar
  54. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC et al (1998) Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 133:424–428PubMedGoogle Scholar
  55. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA (1999) Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 83:231–239PubMedGoogle Scholar
  56. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF et al (1998) Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279:1181–1186PubMedGoogle Scholar
  57. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N et al (2001) Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108:E48PubMedGoogle Scholar
  58. Konig P (1997) Evidence for benefits of early intervention with non-steroidal drugs in asthma. Pediatr Pulmonol Suppl 15:34–39PubMedGoogle Scholar
  59. Laitinen A, Laitinen LA (1994a) Airway morphology: epithelium/basement membrane. Am J Respir Crit Care Med 150:S14–S17PubMedGoogle Scholar
  60. Laitinen LA, Laitinen A (1994b) Modulation of bronchial inflammation: corticosteroids and other therapeutic agents. Am J Respir Crit Care Med 150:S87–S90PubMedGoogle Scholar
  61. Laitinen LA, Laitinen A, Haahtela T (1992) A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 90:32–42PubMedGoogle Scholar
  62. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I et al (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160:1862–1868PubMedGoogle Scholar
  63. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV et al (2001) Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285:2594–2603PubMedGoogle Scholar
  64. Levy M (1995) A fresh angle of attack in asthma? Practitioner 239:450–453PubMedGoogle Scholar
  65. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S et al (2007) Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 119:817–825PubMedGoogle Scholar
  66. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A et al (2005) The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 95:66–71PubMedGoogle Scholar
  67. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ (2003) Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124:70–74PubMedGoogle Scholar
  68. Martinez FD (1995) Viral infections and the development of asthma. Am J Respir Crit Care Med 151:1644–1647, discussion 7–8PubMedGoogle Scholar
  69. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ (1995) Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 332:133–138PubMedGoogle Scholar
  70. Masoli M, Weatherall M, Holt S, Beasley R (2004) Systematic review of the dose–response relation of inhaled fluticasone propionate. Arch Dis Child 89:902–907PubMedGoogle Scholar
  71. Masoli M, Weatherall M, Holt S, Beasley R (2005) Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 60:730–734PubMedGoogle Scholar
  72. Morgan MDL, Higgins BG (2003) The new BTS/SIGN asthma guidelines: where evidence leads the way. Thorax 58:95–96PubMedGoogle Scholar
  73. Myers TR (2008) Guidelines for asthma management: a review and comparison of 5 current guidelines. Respir Care 53:751–767, discussion 67–9PubMedGoogle Scholar
  74. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP et al (1998) Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 102:935–942PubMedGoogle Scholar
  75. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P et al (2004) Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113:59–65PubMedGoogle Scholar
  76. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15–26PubMedGoogle Scholar
  77. NHLBI (1991) Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report (EPR 1991). J Allergy Clin Immunol 88:425–534Google Scholar
  78. NHLBI (1997) Expert panel report 2: guidelines for the diagnosis and management of asthma. National Institute of Health, Bethesda, MDGoogle Scholar
  79. NHLBI (2002) Quick reference for the NAEPP expert panel report: guidelines for the diagnosis and management of asthma–update on selected topics 2002. US Department of Health and Human Services, National Institutes of Health, Bethesda, MDGoogle Scholar
  80. NHLBI (2007) National asthma education and prevention program expert panel report 3: guidelines for the diagnosis and management of asthma full report 2007, Vol. 120. National Heart, Lung, and Blood Institute, Bethesda, MD, pp. S94–S138
  81. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171:129–136PubMedGoogle Scholar
  82. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR et al (2005) Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 147:213–220PubMedGoogle Scholar
  83. Paull K, Covar R, Jain N, Gelfand EW, Spahn JD (2005) Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999–2002. Pediatr Pulmonol 39:311–317PubMedGoogle Scholar
  84. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ et al (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337:1405–1411PubMedGoogle Scholar
  85. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV et al (2003) Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361:1071–1076PubMedGoogle Scholar
  86. Pearlman DS, Lampl KL, Dowling PJ Jr, Miller CJ, Bonuccelli CM (2000) Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 22:732–747PubMedGoogle Scholar
  87. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ et al (2007) Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 356:2027–2039PubMedGoogle Scholar
  88. Petty TL, Rollins DR, Christopher K, Good JT, Oakley R (1989) Cromolyn sodium is effective in adult chronic asthmatics. Am Rev Respir Dis 139:694–701PubMedGoogle Scholar
  89. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG (2006) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368:744–753PubMedGoogle Scholar
  90. Rafferty P, Tucker LG, Frame MH, Fergusson RJ, Biggs BA, Crompton GK (1985) Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisolone-sparing effects. Br J Dis Chest 79:244–250PubMedGoogle Scholar
  91. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158:1213–1220PubMedGoogle Scholar
  92. Ringbaek TJ, Soes-Petersen U, Christensen M, Iversen ET, Rasmussen FV (1996) Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily. Ugeskr Laeger 158:3940–3943PubMedGoogle Scholar
  93. Russell G, Williams DA, Weller P, Price JF (1995) Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 75:423–428PubMedGoogle Scholar
  94. Schatz M, Dombrowski MP, Wise R, Thom EA, Landon M, Mabie W et al (2003) Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 112:283–288PubMedGoogle Scholar
  95. Schatz M, Mosen D, Apter AJ, Zeiger RS, Vollmer WM, Stibolt TB et al (2005) Relationships among quality of life, severity, and control measures in asthma: an evaluation using factor analysis. J Allergy Clin Immunol 115:1049–1055PubMedGoogle Scholar
  96. Sheffer AL, Taggart VS (1991) The National Asthma Education Program. Expert panel report guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. J Allergy Clin Immunol 31:425–534Google Scholar
  97. Silverman M, Connolly NM, Balfour-Lynn L, Godfrey S (1972) Long-term trial of disodium cromoglycate and isoprenaline in children with asthma. Br Med J 3:378–381PubMedGoogle Scholar
  98. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G et al (2001) Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 138:694–698PubMedGoogle Scholar
  99. Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD et al (2007) Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119:64–72PubMedGoogle Scholar
  100. Spahn JD, Szefler SJ (1996) The etiology and control of bronchial hyperresponsiveness in children. Curr Opin Pediatr 8:591–596PubMedGoogle Scholar
  101. Spahn JD, Cherniack R, Paull K, Gelfand EW (2004) Is forced expiratory volume in one second the best measure of severity in childhood asthma? Am J Respir Crit Care Med 169:784–786PubMedGoogle Scholar
  102. Spector SL, Smith LJ, Glass M (1994) Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 150:618–623PubMedGoogle Scholar
  103. Sporik R, Holgate ST, Cogswell JJ (1991) Natural history of asthma in childhood–a birth cohort study. Arch Dis Child 66:1050–1053PubMedGoogle Scholar
  104. Strunk RC, Sternberg AL, Bacharier LB, Szefler SJ (2002) Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. J Allergy Clin Immunol 110:395–403PubMedGoogle Scholar
  105. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B (2000) Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332–336PubMedGoogle Scholar
  106. Szefler SJ (2002) The natural history of asthma and early intervention. J Allergy Clin Immunol 109:S549–S553PubMedGoogle Scholar
  107. Szefler SJ (2011a) Advancing asthma care: the glass is only half full! J Allergy Clin Immunol 128:485–494PubMedGoogle Scholar
  108. Szefler SJ (2011b) Is it time to revise the asthma guidelines? J Allergy Clin Immunol 128:937–938PubMedGoogle Scholar
  109. Tashkin DP, Nathan RA, Howland WC, Minkwitz MC, Simonson SG, Bonuccelli CM (1999) An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. J Allergy Clin Immunol 103:246–254PubMedGoogle Scholar
  110. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H et al (1997) Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 10:2754–2760PubMedGoogle Scholar
  111. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI (2000) Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 30:97–105PubMedGoogle Scholar
  112. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF (1992) Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis 146:547–554PubMedGoogle Scholar
  113. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF (1997) One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 156:688–695PubMedGoogle Scholar
  114. Vollmer WM, Markson LE, O’Connor E, Sanocki LL, Fitterman L, Berger M et al (1999) Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 160:1647–1652PubMedGoogle Scholar
  115. Wallaert B, Brun P, Ostinelli J, Murciano D, Champel F, Blaive B et al (1999) A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group. Respir Med 93:33–38PubMedGoogle Scholar
  116. Wolfenden LL, Diette GB, Krishnan JA, Skinner EA, Steinwachs DM, Wu AW (2003) Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med 163:231–236PubMedGoogle Scholar
  117. Woolcock A, Lundback B, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153:1481–1488PubMedGoogle Scholar
  118. Zimmerman B, D’Urzo A, Berube D (2004) Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol 37:122–127PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Department of Internal MedicineUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations